Regulatory S16 Ep40: FDA Approval Insights: Zongertinib for HER2 TKD-Mutated NSCLC: With Julia Rotow, MD; and Martin Dietrich, MD, PhD OncLive PodcastIn today's episode, we spoke with Julia Rotow, MD, and Martin Dietrich, MD, PhD.RegulatoryOncologyRead full story pharminent March 30, 2026 (Last updated: March 31, 2026) OncLive Podcast In today’s episode, we spoke with Julia Rotow, MD, and Martin Dietrich, MD, PhD. RegulatoryOncologyRead full story Post navigation Previous: Blackstone closes $6.3B fund for life sciences investingNext: AZ considers filings for long-acting Strensiq follow-up Related Stories Regulatory Scholar Rock’s muscle-targeting SMA therapy Isemblyd lands FDA approval pharminent September 14, 2026 Regulatory Psychedelic therapies ride wave of public favor into FDA hearing pharminent September 14, 2026 Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026